Tri-functional antibody to OSCC and complement regulatory proteins

我们已经研究了抗MUC1抗体与口腔鳞状细胞癌（OSCC）的抗肿瘤活性。我们假设抑制补体调节蛋白（CRP）可以增强抗肿瘤活性。因此，逆转肿瘤细胞表面上表达的补体调节蛋白的作用将允许更有效的免疫介导的肿瘤细胞清除，并改善成功免疫治疗的前景。当将用抗MUC1 mAb和抑制性CD55或CD59 mAb两者处理的补体依赖性细胞毒性与单独的抗MUC1 mAb处理进行比较时，分别观察到C依赖性细胞溶解增加2至3倍。还提出了产生识别MUC1和CRP的三功能抗体。本研究成功制备了三功能抗体的表达载体。

We have studied the anti-tumor activities of an anti-MUC1 antibody with oral squamous cell carcinoma (OSCC). We hypothesized the inhibition of complement regulatory proteins (CRPs) could enhance anti-tumor activity. Therefore, that reversing the effects of complement regulatory proteins expressed on a tumor cell surface will allow more effective immune-mediated clearance of tumor cells and improve prospects for successful immunotherapy. When the complement-dependent cytotoxicity was compared treatment with both an anti-MUC1 mAb and inhibiting mAbs of CD55 or CD59 to an anti-MUC1 mAb alone, a 2- to 3-fold increase in C-dependent cell lysis was observed, respectively. It was also proposed to produce the tri-functional antibodies recognized both MUC1 and CRPs. We done to produce the expression vectors of tri-functional antibodies.